Literature DB >> 27561195

Comparison of Characteristics and Outcomes of Heart Failure Patients With Preserved Versus Reduced Ejection Fraction in a Multiethnic Southeast Asian Cohort.

Michael Ross MacDonald1, Pang Ping Wee2, Yan Cao2, Dong Mei Yang2, Sheldon Lee2, Khim Leng Tong2, Kui Toh Gerard Leong2.   

Abstract

There are few data comparing the patient characteristics and outcomes of heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced EF (HFrEF) in Asian cohorts. We aimed to evaluate the prevalence, clinical characteristics, and 1-year outcomes of a well-defined Southeast Asian HFpEF cohort in comparison to an HFrEF cohort. We conducted a retrospective observational study of 1,978 patients discharged from Changi General Hospital, Singapore with a primary diagnosis of HF from 2009 to 2013. About 29% of discharges had HFpEF. Patients with HFpEF were more likely to be women, older age, and have a higher prevalence of hypertension. There were no significant differences in the absolute rates of 30-day outcomes between the 2 groups. The absolute rate of death at 1 year was similar in HFrEF and HFpEF at 17% and 15%, respectively (p = 0.3). After multivariate adjustment, there was no difference in the outcomes of the 2 groups. Atrial fibrillation at baseline was a predictor of death or HF hospitalization in HFpEF but not HFrEF (interaction p = 0.003). In conclusion, in this study of a Southeast Asian population with well-defined HF, we found that the clinical profile of patients with HF was similar to that in the West and 30-day and 1-year mortality and morbidity were not significantly different between cohorts.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27561195     DOI: 10.1016/j.amjcard.2016.07.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.

Authors:  Xiaojing Chen; Gianluigi Savarese; Ulf Dahlström; Lars H Lund; Michael Fu
Journal:  Clin Res Cardiol       Date:  2019-04-12       Impact factor: 5.460

2.  Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study.

Authors:  Tomas Lapinskas; Sebastian Kelle; Jana Grune; Anna Foryst-Ludwig; Heike Meyborg; Sarah Jeuthe; Ernst Wellnhofer; Ahmed Elsanhoury; Burkert Pieske; Rolf Gebker; Ulrich Kintscher; Philipp Stawowy
Journal:  J Am Heart Assoc       Date:  2020-01-31       Impact factor: 5.501

3.  Risks of incident heart failure with preserved ejection fraction in Chinese patients hospitalized for cardiovascular diseases.

Authors:  Jun-Xia Zhang; Yi-Xian Liu; Chun-Lei Xia; Peng Chu; Xin-Liang Qu; Lin-Lin Zhu; Shao-Liang Chen
Journal:  J Geriatr Cardiol       Date:  2019-12       Impact factor: 3.327

4.  Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry.

Authors:  Michael R MacDonald; Wan Ting Tay; Tiew-Hwa Katherine Teng; Inder Anand; Lieng Hsi Ling; Jonathan Yap; Jasper Tromp; Gurpreet S Wander; Ajay Naik; Tachapong Ngarmukos; Bambang B Siswanto; Chung-Lieh Hung; A Mark Richards; Carolyn S P Lam
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

5.  Acute decompensated heart failure in a non cardiology tertiary referral centre, Sarawak General Hospital (SGH-HF).

Authors:  Hwei Sung Ling; Bui Khiong Chung; Pin Fen Chua; Kai Xin Gan; Wai Leng Ho; Elora Yoke Ling Ong; Cindy Hui San Kueh; Yie Ping Chin; Alan Yean Yip Fong
Journal:  BMC Cardiovasc Disord       Date:  2020-12-07       Impact factor: 2.298

6.  Association of left ventricular ejection fraction with contrast-induced nephropathy and mortality following coronary angiography or intervention in patients with heart failure.

Authors:  Kun Wang; Hua-Long Li; Wei-Jie Bei; Xiao-Sheng Guo; Shi-Qun Chen; Sheikh Mohammed Shariful Islam; Ji-Yan Chen; Yong Liu; Ning Tan
Journal:  Ther Clin Risk Manag       Date:  2017-07-19       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.